SEC Filing Summary: Galena Biopharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Galena Biopharma, Inc. on September 28, 2011. The report discloses the closing of a private equity transaction that occurred on the same date. Note: The request metadata references "SELLAS Life Sciences Group, Inc.," but the filing text explicitly identifies the registrant as Galena Biopharma, Inc.
Key Financial Metrics
The filing details a capital raise event rather than periodic financial performance metrics. Specific figures include:
- Shares Issued: 700,000 shares of common stock.
- Purchase Price: $0.65 per share.
- Total Proceeds: $455,000 aggregate purchase price.
- Investors: Two institutional investors.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of this specific transaction.
Material Changes
The primary material change is the increase in outstanding common stock and cash assets resulting from the closing of the amended and restated investor subscription agreement entered into on September 26, 2011. The shares were sold pursuant to a shelf registration statement on Form S-3 (File No. 333-167025) declared effective on May 28, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the equity issuance. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the current share count and dilution impact of the 700,000 newly issued shares.
- Confirm the identity of the two institutional investors involved in the transaction.
- Review the attached legal opinion (Exhibit 5.1) from TroyGould PC regarding the validity of the share issuance.
- Check subsequent filings for the utilization of the $455,000 in raised capital.